Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mark A. Stang who wrote (3053)	12/5/1997 1:17:00 AM
From: RT	Respond to of 23519

Mark, Harvard Scientific's product is administered exactly like Vivus's. That's why Vivus has sued for patent infringment. I believe their product is in a liquid form. This year HVSF has gone from 9 to 1. I wonder why? RT

To: Mark A. Stang who wrote (3053)	12/5/1997 8:17:00 AM
From: Edderd	Read Replies (2) \| Respond to of 23519

Mark, At the last AUA meeeting the "product" was presented. It consists of lyophilized (?freeze dried) PGe which is instantly activated by a simple solution and is administered into the urethra, PAINLESSLY. It has a shelf life of over 3 yrs. The major drawback of MUSE is that many people get urethral burning enough to stop using the drug. It is really a definite threat to MUSE and would probably replace it unless the problem of burning is stopped. I know Vivus is working on this problem. Something to worry about. Ed